# Paul Bolno

Type: Person

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/paul-bolno
Canonical HTML page: https://gethealthbrief.com/entity/paul-bolno

## Timeline

- **2026-02-26**: FY 2025 Earnings — Wave and Collegium release full-year financial results and 2026 guidance.
- **2026**: Anticipated Filing — Expected regulatory submission for WVE-N531 in Duchenne muscular dystrophy.
- **2025-Q4**: RNA Editing Milestone — WVE-006 demonstrates successful RNA editing in AATD patients.
- **2025-Q2**: DMD Breakthrough — Wave reports industry-leading dystrophin expression for WVE-N531.

## Recent coverage (2 stories)

### Wave's Obesity siRNA Shows 16.5% Visceral Fat Improvement, Targeting 175M Patients
2026-08-04 03:59:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences' WVE-007, a novel siRNA silencing Activin E, demonstrated a 16.5% improvement in visceral fat-to-muscle ratio in Phase I, outpacing existing therapies and offering a potential solution for the 70% of GLP-1 users who discontinue within a year. With enrollment underway in the INLIGHT Phase IIa trial, the 175 million individuals with obesity in the U.S. and Europe may soon have a longer-lasting, disease-modifying option.
Full story: https://gethealthbrief.com/story/wave-obesity-siRNA-16-5-vmr

### Wave Life Sciences and Collegium Report 2025 Results Amid RNA Breakthroughs
2026-02-26 14:24:42 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wave Life Sciences and Collegium Pharmaceutical released their Q4 and full-year 2025 results, highlighting a pivotal year for RNA editing and specialty pain management. Wave's transition toward a commercial-stage biotech is accelerated by its GSK partnership and landmark clinical data in Alpha-1 antitrypsin deficiency.
Full story: https://gethealthbrief.com/story/wave-life-sciences-collegium-2025-financials-rna-editing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.